Is Vaxart Stock a Good Investment?
Vaxart Investment Advice | VXRT |
- Examine Vaxart's financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Vaxart's leadership team and their track record. Good management can help Vaxart navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Vaxart's business and its evolving consumer preferences.
- Compare Vaxart's performance and market position to its competitors. Analyze how Vaxart is positioned in terms of product offerings, innovation, and market share.
- Check if Vaxart pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Vaxart's stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Vaxart Inc stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Vaxart Inc is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Weak | Details | |
Volatility | Out of control | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Fairly Valued | Details | |
Odds Of Distress | Very High | Details | |
Economic Sensitivity | Responds to the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unavailable | Details |
Examine Vaxart Stock
Researching Vaxart's stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 16.0% of the company outstanding shares are owned by institutional investors. The company has Price to Book (P/B) ratio of 1.9. Historically many companies with similar price-to-book (P/B) ratio do better than the market in the long run. Vaxart Inc recorded a loss per share of 0.4. The entity last dividend was issued on the 9th of November 2012. The firm had 1:11 split on the 14th of February 2018.
To determine if Vaxart is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Vaxart's research are outlined below:
| Vaxart Inc had very high historical volatility over the last 90 days | |
| Vaxart Inc has some characteristics of a very speculative penny stock | |
| Vaxart Inc has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 7.38 M. Net Loss for the year was (82.47 M) with loss before overhead, payroll, taxes, and interest of (49.5 M). | |
| Vaxart Inc currently holds about 129.55 M in cash with (70.45 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.02, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Latest headline from MacroaxisInsider: Acquisition by Phillip Lee of 410000 shares of Vaxart at 0.78 subject to Rule 16b-3 |
Vaxart Quarterly Cash And Short Term Investments |
|
Vaxart uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Vaxart Inc. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Vaxart's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 20th of March 2024 Upcoming Quarterly Report | View | |
| 2nd of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 20th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Vaxart's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Vaxart's investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2020-11-12 | 2020-09-30 | -0.09 | -0.08 | 0.01 | 11 | ||
2024-03-14 | 2023-12-31 | -0.14 | -0.12 | 0.02 | 14 | ||
2023-08-03 | 2023-06-30 | -0.18 | -0.16 | 0.02 | 11 | ||
2020-05-12 | 2020-03-31 | -0.04 | -0.02 | 0.02 | 50 | ||
2024-10-31 | 2024-09-30 | -0.0933 | -0.06 | 0.0333 | 35 | ||
2022-05-09 | 2022-03-31 | -0.16 | -0.2 | -0.04 | 25 | ||
2021-05-03 | 2021-03-31 | -0.1 | -0.14 | -0.04 | 40 | ||
2023-03-15 | 2022-12-31 | -0.23 | -0.18 | 0.05 | 21 |
Know Vaxart's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Vaxart is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Vaxart Inc backward and forwards among themselves. Vaxart's institutional investor refers to the entity that pools money to purchase Vaxart's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Susquehanna International Group, Llp | 2024-12-31 | 328.8 K | Iht Wealth Management, Llc | 2024-12-31 | 220.7 K | Raymond James Finl Svs Advisors, Inc. | 2024-09-30 | 188.4 K | Bank Of America Corp | 2024-12-31 | 184.4 K | Charles Schwab Investment Management Inc | 2024-12-31 | 153.5 K | Jane Street Group Llc | 2024-12-31 | 124.7 K | Morgan Stanley - Brokerage Accounts | 2024-12-31 | 106.7 K | Group One Trading, Lp | 2024-12-31 | 105.9 K | Hrt Financial Llc | 2024-12-31 | 91.3 K | Sio Capital Management, Llc | 11.5 M | Vanguard Group Inc | 2024-12-31 | 10.1 M |
Vaxart's market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 132.85 M.Market Cap |
|
Vaxart's profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.14) | (1.09) | |
| Return On Capital Employed | (1.23) | (1.17) | |
| Return On Assets | (1.03) | (0.98) | |
| Return On Equity | (1.64) | (1.56) |
Determining Vaxart's profitability involves analyzing its financial statements and using various financial metrics to determine if Vaxart is a good buy. For example, gross profit margin measures Vaxart's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Vaxart's profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Vaxart's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Vaxart Inc. Check Vaxart's Beneish M Score to see the likelihood of Vaxart's management manipulating its earnings.
Evaluate Vaxart's management efficiency
Vaxart Inc has return on total asset (ROA) of (0.3291) % which means that it has lost $0.3291 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.0337) %, meaning that it created substantial loss on money invested by shareholders. Vaxart's management efficiency ratios could be used to measure how well Vaxart manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to gain to -1.09 in 2025. Return On Capital Employed is likely to gain to -1.17 in 2025. At this time, Vaxart's Total Current Liabilities is comparatively stable compared to the past year. Liabilities And Stockholders Equity is likely to gain to about 150.6 M in 2025, whereas Non Current Liabilities Other is likely to drop slightly above 3.2 M in 2025.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 0.46 | 0.44 | |
| Tangible Book Value Per Share | 0.39 | 0.37 | |
| Enterprise Value Over EBITDA | (1.19) | (1.25) | |
| Price Book Value Ratio | 1.65 | 2.34 | |
| Enterprise Value Multiple | (1.19) | (1.25) | |
| Price Fair Value | 1.65 | 2.34 | |
| Enterprise Value | 67.2 M | 127.8 M |
The strategic initiatives led by Vaxart's management are central to its market success. By analyzing these initiatives, we provide a clear picture of the stock's growth prospects.
Beta 1.696 |
Basic technical analysis of Vaxart Stock
As of the 20th of March, Vaxart has the Coefficient Of Variation of 3985.72, risk adjusted performance of 0.031, and Semi Deviation of 6.25. In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Vaxart Inc, as well as the relationship between them.Vaxart's insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Vaxart insiders, such as employees or executives, is commonly permitted as long as it does not rely on Vaxart's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Vaxart insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Vaxart's Outstanding Corporate Bonds
Vaxart issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Vaxart Inc uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Vaxart bonds can be classified according to their maturity, which is the date when Vaxart Inc has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Valero Energy Partners Corp BondUS91914JAA07 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View |
Understand Vaxart's technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Vaxart's various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.031 | |||
| Market Risk Adjusted Performance | 0.1447 | |||
| Mean Deviation | 4.58 | |||
| Semi Deviation | 6.25 | |||
| Downside Deviation | 7.83 | |||
| Coefficient Of Variation | 3985.72 | |||
| Standard Deviation | 7.06 | |||
| Variance | 49.91 | |||
| Information Ratio | 0.0343 | |||
| Jensen Alpha | 0.2603 | |||
| Total Risk Alpha | 0.7637 | |||
| Sortino Ratio | 0.0309 | |||
| Treynor Ratio | 0.1347 | |||
| Maximum Drawdown | 49.25 | |||
| Value At Risk | (7.95) | |||
| Potential Upside | 11.9 | |||
| Downside Variance | 61.24 | |||
| Semi Variance | 39.07 | |||
| Expected Short fall | (5.99) | |||
| Skewness | (0.29) | |||
| Kurtosis | 5.18 |
| Risk Adjusted Performance | 0.031 | |||
| Market Risk Adjusted Performance | 0.1447 | |||
| Mean Deviation | 4.58 | |||
| Semi Deviation | 6.25 | |||
| Downside Deviation | 7.83 | |||
| Coefficient Of Variation | 3985.72 | |||
| Standard Deviation | 7.06 | |||
| Variance | 49.91 | |||
| Information Ratio | 0.0343 | |||
| Jensen Alpha | 0.2603 | |||
| Total Risk Alpha | 0.7637 | |||
| Sortino Ratio | 0.0309 | |||
| Treynor Ratio | 0.1347 | |||
| Maximum Drawdown | 49.25 | |||
| Value At Risk | (7.95) | |||
| Potential Upside | 11.9 | |||
| Downside Variance | 61.24 | |||
| Semi Variance | 39.07 | |||
| Expected Short fall | (5.99) | |||
| Skewness | (0.29) | |||
| Kurtosis | 5.18 |
Consider Vaxart's intraday indicators
Vaxart intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Vaxart stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Accumulation Distribution | 283448.0 | |||
| Daily Balance Of Power | (0.18) | |||
| Rate Of Daily Change | 0.98 | |||
| Day Median Price | 0.55 | |||
| Day Typical Price | 0.56 | |||
| Price Action Indicator | 0.0066 | |||
| Period Momentum Indicator | (0.01) | |||
| Relative Strength Index | 45.92 |
Vaxart Stock media impact
Far too much social signal, news, headlines, and media speculation about Vaxart that are available to investors today. That information is available publicly through Vaxart media outlets and privately through word of mouth or via Vaxart internal channels. However, regardless of the origin, that massive amount of Vaxart data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Vaxart news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Vaxart relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Vaxart's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Vaxart alpha.
Vaxart Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Vaxart can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Vaxart Corporate Management
| Sarah Khan | VP Resources | Profile | |
| Rajesh Kapoor | Senior Quality | Profile | |
| Shaily Garg | Senior Management | Profile | |
| Brant Biehn | Sr Operations | Profile | |
| Cezar MBA | Pres CEO | Profile |
Additional Tools for Vaxart Stock Analysis
When running Vaxart's price analysis, check to measure Vaxart's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vaxart is operating at the current time. Most of Vaxart's value examination focuses on studying past and present price action to predict the probability of Vaxart's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vaxart's price. Additionally, you may evaluate how the addition of Vaxart to your portfolios can decrease your overall portfolio volatility.